Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation

ABSTRACTPurposeThe aim of this study was to develop a Bayesian dose individualisation tool for warfarin. This was incorporated into the freely available software TCIWorks (www.tciworks.info) for use in the clinic.MethodsAll pharmacokinetic and pharmacodynamic (PKPD) models for warfarin in the medical literature were identified and evaluated against two warfarin datasets. The model with the best external validity was used to develop an optimal design for Bayesian parameter control. The performance of this design was evaluated using simulation-estimation techniques. Finally, the model was implemented in TCIWorks.ResultsA recently published warfarin KPD model was found to provide the best fit for the two external datasets. Optimal sampling days within the first 14 days of therapy were found to be days 3, 4, 5, 11, 12, 13 and 14. Simulations and parameter estimations suggested that the design will provide stable estimates of warfarin clearance and EC50. A single patient example showed the potential clinical utility of the method in TCIWorks.ConclusionsA Bayesian dose individualisation tool for warfarin was developed. Future research to assess the predictive performance of the tool in warfarin patients is required.

[1]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[2]  E. Chan,et al.  Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model , 1994, Clinical pharmacology and therapeutics.

[3]  D. Mungall,et al.  Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation. , 1985, Therapeutic drug monitoring.

[4]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[5]  David C. Anderson,et al.  Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. , 1996, Archives of internal medicine.

[6]  L Aarons,et al.  A pharmacokinetic simulation model for ivabradine in healthy volunteers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  L. B. Wingard,et al.  Pharmacokinetics of warfarin enantiomers: A search for intrasubject correlations , 1978, Clinical pharmacology and therapeutics.

[8]  L. Kalra,et al.  Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness , 2000, BMJ : British Medical Journal.

[9]  D. Berlowitz,et al.  Warfarin dose management affects INR control , 2009, Journal of thrombosis and haemostasis : JTH.

[10]  M. Pirmohamed,et al.  Pharmacogenetics of warfarin: current status and future challenges , 2007, The Pharmacogenomics Journal.

[11]  Stephen B. Duffull,et al.  The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..

[12]  R A O'REILLY,et al.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.

[13]  P. Deloukas,et al.  A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age , 2010, Clinical pharmacology and therapeutics.

[14]  T. Theofanous,et al.  Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.

[15]  A. Gallus,et al.  Assessment of an Age-Adjusted Warfarin Initiation Protocol , 2003, The Annals of pharmacotherapy.

[16]  A. Forster,et al.  Frequency of adverse events in patients with poor anticoagulation: a meta-analysis , 2007, Canadian Medical Association Journal.

[17]  R L Berg,et al.  Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.

[18]  M. Leaning,et al.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy. , 1999, British journal of clinical pharmacology.

[19]  Janice D Nunnelee,et al.  Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64. , 2009, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[20]  J. Vilpo,et al.  Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents. , 2005, Clinical chemistry.

[21]  L B Sheiner,et al.  Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.

[22]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[23]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[24]  A. McLachlan,et al.  Investigation of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic‐Pharmacodynamic Modeling Approach , 2006, Journal of clinical pharmacology.

[25]  Malcolm Rowland,et al.  Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults , 1993 .

[26]  A. Forster,et al.  Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis , 2008, Canadian Medical Association Journal.

[27]  R. Pendleton,et al.  Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study , 2010, Therapeutic drug monitoring.

[28]  Y. Caraco,et al.  CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.

[29]  L. Aarons,et al.  Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  M. Moia,et al.  Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). , 2001, Haematologica.

[31]  P. J. Ryan,et al.  Computer control of anticoagulant dose for therapeutic management. , 1989, BMJ.

[32]  D. Pennell,et al.  Cardiovascular magnetic resonance of left ventricular pseudoaneurysm , 2005, Heart.

[33]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[34]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[35]  A. Abdelhafiz,et al.  Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit. , 2007, The American journal of geriatric pharmacotherapy.

[36]  P M Aggeler,et al.  Studies on Coumarin Anticoagulant Drugs: Initiation of Warfarin Therapy Without a Loading Dose , 1968, Circulation.

[37]  A. Forster,et al.  Effect of study setting on anticoagulation control: a systematic review and metaregression. , 2006, Chest.

[38]  D. Mungall,et al.  Pharmacodynamics of Warfarin at Steady State , 1987, Therapeutic drug monitoring.

[39]  L. Aarons,et al.  A Bayesian Method Based on Clotting Factor Activity for the Prediction of Maintenance Warfarin Dosage Regimens , 2003, Therapeutic Drug Monitoring.

[40]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[41]  J. Jespersen,et al.  Multicentre randomised study of computerised anticoagulant dosage , 1998, The Lancet.

[42]  E N Jonsson,et al.  A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy , 2007, Clinical pharmacology and therapeutics.

[43]  L B Sheiner,et al.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.

[44]  R. Day,et al.  Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects , 2008, British journal of pharmacology.

[45]  L B Sheiner,et al.  Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.

[46]  R. Gieschke,et al.  Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[47]  A. Forster,et al.  Effect of Study Setting on Anticoagulation Control * , 2006 .

[48]  A M Vossepoel,et al.  A computer program for long term anticoagulation control. , 1977, Computer programs in biomedicine.

[49]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[50]  David G. Covell,et al.  Systems and Microcomputer Approach to Anticoagulant Therapy , 1980, IEEE Transactions on Biomedical Engineering.

[51]  T J O'Leary,et al.  Evaluation of a computer‐assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model , 1982, Clinical pharmacology and therapeutics.